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Abstract
Galectins are pleiotropic carbohydrate-binding lectins involved in inflammation,
growth/differentiation, and tissue remodeling. The functional role of galectins
in amyotrophic lateral sclerosis (ALS) is unknown. Expression studies revealed
increases in galectin-1 mRNA and protein in spinal cords from SOD1G93A mice,
and in galectin-3 and -9 mRNAs and proteins in spinal cords of both
SOD1G93A mice and sporadic ALS patients. As the increase in galectin-3
appeared in early presymptomatic stages and increased progressively through to
end stage of disease in the mouse, it was selected for additional study, where it
was found to be mainly expressed by microglia. Galectin-3 antagonists are not
selective and do not readily cross the blood–brain barrier; therefore, we generated SOD1G93A/Gal-3 / transgenic mice to evaluate galectin-3 deletion in a
widely used mouse model of ALS. Disease progression, neurological symptoms,
survival, and inflammation were assessed to determine the effect of galectin-3
deletion on the SOD1G93A disease phenotype. Galectin-3 deletion did not
change disease onset, but resulted in more rapid progression through functionally defined disease stages, more severely impaired neurological symptoms at all
stages of disease, and expiration, on average, 25 days earlier than SOD1G93A/
Gal-3+/+ cohorts. In addition, microglial staining, as well as TNF-a, and oxidative injury were increased in SOD1G93A/Gal-3 / mice compared with
SOD1G93A/Gal-3+/+ cohorts. These data support an important functional role
for microglial galectin-3 in neuroinflammation during chronic neurodegenerative disease. We suggest that elevations in galectin-3 by microglia as disease
progresses may represent a protective, anti-inflammatory innate immune
response to chronic motor neuron degeneration.

Introduction
Amyotrophic lateral sclerosis (ALS) is heterogeneous in
phenotype and genotype, and despite intense research
effort, the underlying cause(s) remain obscure. Sporadic
and familial forms of ALS share common pathophysiological features, including a marked neuroinflammatory
response, characterized by glial activation and innate and

adaptive inflammatory components (for reviews, see
Ilieva et al. 2009 and Appel et al. 2011). In murine models of ALS, activated astrocytes and microglia are observed
in neuroinflammatory foci in the spinal cord prior to
onset of symptoms, and such areas correlate with pronounced regional motor neuron loss (Shibata et al. 1996).
Infiltration of CD8+ T-suppressor/cytotoxic and CD4+
T helper cells is also prominent (Kawamata et al. 1992).
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These cells alter disease progression both independently
and through apparent cross-talk with microglia (Kipnis
et al. 2004; Beers et al. 2008). Generally, glia secrete soluble factors that may be toxic (reactive oxygen species,
proinflammatory cytokines) or protective (growth factors), depending on local environment (Li et al. 2007).
However, in models of ALS, transgenic expression of
mutant hSOD1 in astrocytes and microglia results in glial
phenotypes that are inherently neurotoxic compared to
their wild-type counterparts (Boillee et al. 2006; Nagai
et al. 2007). Thus, chronic neurodegeneration in ALS may
evolve as a so-called noncell-autonomous process (Lobsiger and Cleveland 2007) that, in part, reflects a toxic glial
microenvironment.
Galectins are multifunctional immunomodulatory
lectins that are expressed by a variety of cells during normal development and in inflammatory or autoimmune
diseases and cancer (reviewed in Norling et al. 2009).
Recent observations that galectins are increased after
acute CNS injuries and during chronic neurodegeneration
(Byrnes et al. 2006; Zhou et al. 2010) may support a
potential role for galectins in the adaptive immune
response to the “threat” of cell stress, damage, or death,
and potentially, in the repair function(s) of innate immunity (Kono and Rock 2008). Galectins contain a conserved carbohydrate recognition domain (CRD) with
affinity for b-galactosides. They are secreted via a nonclassical pathway, but also found in intracellular compartments (Gong et al. 1999; Hughes 1999). Extracellularly,
galectins form cross-links with cell surface glycoconjugates
or the extracellular matrix, where they preferentially bind
N-acetyllactosamine (Galß13GlcNAc or Galß1-4GlcNAC)
residues. Because many cell surface receptors, including
those for cytokines, growth factors, and neurotransmitters, contain glycoconjugates, galectins may modulate
transmembrane signaling events that affect a variety of
cell functions (Boscher et al. 2011).
Recently, expression profiling revealed increases in
mRNA for several galectins within the spinal cord during
late-stage disease in mouse models of ALS (Ferraiuolo
et al. 2007; Gonzalez de Aguilar et al. 2008; Zhou et al.
2010). Expression of galectin-3, also known as Mac-2,
correlates with microglial activation subsequent to neuronal degeneration in mouse models of ALS (Yamanaka
et al. 2008; Saxena et al., 2009; Hossiani et al. 2011), but
nevertheless, its role in the disease is unclear.
In this study, we initially assessed expression of multiple galectins, during chronic motor neuron disease in the
SOD1G93A mouse and in patients with sporadic ALS. As
galectin-3 was the only galectin to progressively increase
from early to late stage of disease in the mouse, and was
also confirmed in patients with sporadic ALS, we then
focused on the role of galectin-3 in disease progression.
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Currently, available galectin-3 antagonists are carbohydrate based and are neither particularly selective, nor able
to cross the blood–brain barrier significantly (Pieters
2006). Therefore, we generated C57BL6 SOD1G93A/
Gal-3 / knock-out transgenic mice for our studies.

Materials and Methods
Animals
Animal procedures were performed following National
Institutes of Health Guidelines for Animal Use and Welfare and supported by an approved institutional animal
protocol. B6SJL (stock no. 002726) or C57BL6 (stock no.
004435) mice with the G93A human SOD1 mutation
(SOD1G93A; Gurney et al. 1994) were obtained from Jackson Laboratories (Bar Harbor, ME). For all studies, data
were collected only from male mice, to avoid confounding issues of disease progression due to sex. The B6SJL
strain was used for the expression studies. To avoid confounding background effects, the SOD1G93A/Gal-3 /
knock-out was created on the C57BL6 SOD1G93A strain,
rather than B6SJL, as the founder galectin-3 knock-outs
were on the C57BL6 background (Hsu et al. 2000).
Female C57BL6 galectin-3 knock-out mice (Gal-3 / ;
Hsu et al. 2000) were bred with nonlittermate transgenic
C57BL6 SOD1G93A males to yield homozygous C57BL6
SOD1G93A/Gal-3 / mice at the F2 generation. Transgenic
offspring were genotyped by PCR amplification from tail
tissue DNA. Briefly, tail clips were digested (12 h, 55°C)
in lysis buffer (1 M Tris, pH8.8, 0.5 M EDTA, 10% Tween
20, 200 lg/mL Proteinase K), boiled (5 min) to inactivate
Proteinase K, and centrifuged at 16,500 9 g (2 min).
PCR lysis buffer was combined directly with PCR reaction
buffer (1X Flexi Buffer, 25 mM MgCl2, 10 mM of PCR
nucleotide mix), primers, GoTaq DNA polymerase, and
nuclease free water in a 50 lL reaction mixture. RT-PCR
was used to amplify mutated SOD1 and disrupted galectin-3, and results visualized on 2% ethidium bromide
agarose gels. Primers used to identify the human
mSOD1G93A gene were 5′-CATCAGCCCTAATCCATCT
GA-3′ (forward) and 5′-CGCGACTAACAATCAAAGTGA3′ (reverse). GaI-3 / mice were originally produced by
interrupting the region coding for the CRD in exon 5, by
inserting a neomycin resistant gene in a short intro
4-exon 5 segment (0.5 kb) (Hsu et al. 2000). Primers to
identify galectin-3 deficient mice were 5′GTAGGTGA
GAGTCACAAGCTGGAGGCC-3′ (binding upstream of
intron) and 5′GTAGGTGAGAGTCACAAGCTGGAGG
CC-3′ (binding upstream of the Neo cassette) and 5′CAC
TCTCAAAGGGGAAGGCTGACTGTC-3′ (binding common downstream sequence of exon). These primers amplify
a 450-bp fragment in gal-3+/+ mice, a 300-bp fragment in
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gal-3 / mice, and both 450- and 300-bp fragments in
gal-3+/ heterozygotes.

Human postmortem spinal cord tissue
Spinal cords from patients with sporadic ALS (n = 5) or
from those who died from other causes (n = 4) were
obtained from a postmortem tissue bank (Johns Hopkins
University). Human samples were evaluated in accordance
with HIPPA regulations and supported by approved IRB
protocols at Johns Hopkins and Children’s National
Medical Center.

RNA preparation and microarray
Lumbar spinal cords from male B6SJL/J SOD1G93A transgenic and wild-type mice were isolated at 28, 42, 56, 70,
98, 112, and 126 days of age (n = 3 per group), extracted
in Trizol (Life Technologies, Grand Island, NY), cleaned
with RNeasy mini-columns (Invitrogen, Carlsbad, CA),
quantified with a spectrophotometer, and assessed for
quality by gel electrophoresis. RNA was considered to be
of suitable quality when intact 28S and 18S ribosomal
bands were visualizable upon ethidium bromide staining
of samples resolved on a 1% agarose gel. Total RNA was
amplified and synthesized as biotin-conjugated cRNA,
fragmented, and hybridized to Mouse 430 2.0 Affymetrix
arrays using reagents and methods supplied by the
manufacturer (Affymetrix, Santa Clara, CA). Microarray
data are publicly available at NCBI GEO (accession
GSE18597). For RT-PCR, cDNA was synthesized from
total RNA with the SuperScript III First-Strand synthesis
system (Invitrogen) and subjected to Taqman RT-PCR on
a ABI Prism 7900HT (Life Technologies). Galectin-3
DNA primer sequ-ences were forward-CGGTCGTAGGT
GAGCATCGTTGAC[FAM]G and reverse-CCCTTTGAGA
GTGGCAAACCAT. Samples (n = 3 per group) were
normalized to the relative amounts of reverse transcribed
GAPDH, and expression levels calculated using 2.2
Sequence Detection Software (all from Applied Biosystems, Foster City, CA).

Western blot, TNF-a, and protein carbonyl
assays
Spinal cord homogenates (n = 3 per group for Western
blot, n = 4 per genotype for TNF-a and carbonyl assays)
were prepared in Mammalian Protein Extraction
Reagent (M-PER) buffer with protease inhibitors (Pierce
Biotechnology, Rockford, IL) and protein concentrations
determined with a BCA protein assay kit (Pierce Biotechnology). Proteins (15 lg) were resolved on 10% tris-glycine or bis-tris polyacrylamide gels and electrotransferred
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to Hybond ECL membranes, as previously described
(Knoblach et al. 2004). Blots were blocked in blocking
buffer (0.05% Tween 20, 5% milk powder in PBS) for
1 h, incubated with primary antibody for 1 h, washed 39
in 0.05% Tween in PBS, and then incubated with antiHRP conjugated secondary antibody for 1 h. Blots were
again washed 39 in 0.05% Tween in PBS, and then developed with an ECL chemiluminescent detection kit (Amersham, Piscataway, NJ) and exposed to film. Primary
antibodies included goat anti-mouse or anti-human
galectin(s)-1, -3, and -9 (1:500; R&D systems, Minneapolis, MN) and antiactin (1:5000; Sigma–Aldrich, St. Louis,
MO). Secondary antibodies included horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit (1:3000;
Bio-Rad, Hercules, CA), or horseradish peroxidaseconjugated donkey anti-goat (1:3000; Santa Cruz Biotechnology, Santa Cruz, CA). For TNF-a, total protein (50 or
150 lg) was assessed in triplicate using a Multi-Analyte
ELISA kit (SABiosciences, Rockville, MD). Protein carbonyls were detected with an OxiSelect Protein Carbonyl
ELISA Kit (Cell Biolabs, San Diego, CA). Absorbance was
read at 450 nm.

Immunohistochemistry
Animals were perfused with PBS and 4% paraformaldehyde and spinal cords were removed, cryoprotected, frozen, and cut (20 lm). Sections (animal or human) were
fixed in 4% paraformaldehyde (10 min), washed in PBS,
and blocked in 5% donkey serum in 0.1% Triton X-100/
PBS (1 h). Primary antibodies were applied (2 h, room
temperature), sections were then washed in PBS, incubated with secondary antibody (1 h, room temperature),
washed again, cover slipped, and viewed with a Bio-Rad
MRC1024 confocal fluorescent microscope. Primary antibodies were as follows: goat anti-galectin-3 (1:500; R&D
Systems), rabbit anti-GFAP (astrocyte marker; 1:1000;
Sigma-Aldrich), and rabbit anti-IBA1 (microglial marker;
1:2000; Wako Chemical, Richmond, VA). These antibodies cross react with both mouse and human. Alexa 488
donkey anti-goat (1:2000; Jackson Immunoresearch Labs,
West Grove, PA) and Alexa 568 donkey anti-rabbit
(1:2000; Invitrogen, Grand Island, NY) were used as
secondary antibodies. For Nissl staining, Alexa Fluor
FITC-conjugated Nissl (1:5000; Invitrogen) was applied to
sections (10 min), and thereafter, sections were again
rinsed in PBS.

Survival and neurological function
Animals (n = 12 per genotype) remained in the study
until they lost the ability to right themselves within 3 sec
after being placed on their back, at which point they were
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removed from study, and categorized as “expired.” For
disease progression, function was rated from score 4 (no
sign of disease on any functional test) to 0 as adapted
from Rouaux et al. (2007), where 3 = reduced limb
extension and/or tremors upon suspension by the tail,
but otherwise appears normal, 2 = deficits on functional
tests (tail suspension, grip, activity, or rotarod), but no
visually obvious abnormalities, 1 = visually obvious unior bilateral paralysis in addition to abnormalities on functional tests, 0 = loss of righting reflex, visually obvious
uni- or bilateral paralysis and abnormalities on functional
tests. Functional tests were as follows: (i) Grip strength:
animals were held so that their hind limbs grasped the
pull bar of a grip strength meter (Columbus instruments,
Columbus, OH) and were pulled forward until their grip
was broken. Data from five trials were normalized to
body weight and expressed as compression/g of body
weight. (ii) Activity test: animals were allowed to freely
ambulate in a 60 9 60 cm open chamber divided into
equal quadrants for 3 min. The number of times they
passed into each quadrant, or reared (vertical rise) during
exploration was recorded. (iii) Rotarod: mice were acclimatized on the rotarod (UgoBasile, VA, Italy) at 10 rpm
(5 min) for 5 days prior to testing. For tests, mice were
placed on the rotarod, and it accelerated from 10 to
54 rpm within 5 min. The time each mouse stayed on
the rotarod was expressed as the latency to fall. The score
shown represents the best single score from three
successive rotarod trials. All functional tests were performed weekly by an investigator blinded to genotype
starting from Week 8 until the animal was classified as
expired.

Statistical methods
Data are expressed as the mean ± standard error of the
mean (SEM) for each group. Functional progression
scores and survival data were assessed with the Kaplan–
Meier statistical test. Other behavioral data were assessed
with two-way ANOVA for the effect of time and score,
followed by individual post hoc t-tests for each time
point. Morphological and biochemical data were evaluated with individual t-tests.

Results
Changes in galectin-9 complement changes
in galectin-3 in spinal cords of SOD1G93A
mice and in patients with sporadic ALS
Galectin-1 mRNA was increased from 42 to 126 days of
age, galectin-9 mRNA from 112 to 126 days of age, and
galectin-3 from 56 to 126 days of age in B6SJL SOD1G93A
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mice, compared with age-matched controls (Fig. 1a). The
expression of galectin-3 protein was measured in spinal
cord and other tissues at 126 days of age, when expression levels were likely to be highest. However, galectin-3
was not increased in supraspinal CNS regions (cerebral
cortex, cerebellum), or in gastrocnemius muscle, which is
affected in ALS and in B6SJL SOD1G93A mice (Fig. 1b).
Rather, it was confined to the spinal cord, where it
increased from 70 to 126 days of age in B6SJL SOD1G93A
mice, compared with age-matched controls (~11-fold
increase from 70 to 126 days of age; Fig. 1c and d).
Galectin-9 protein also increased from 98 to 126 days of
age in B6SJL SOD1G93A mice, whereas galectin-1 protein
was not elevated until 126 days of age (Fig. 1c and d).
These time points correspond to distinct functional stages
in the B6SJL SOD1G93A strain, where 70 days of
age = asymptomatic disease, 98 days of age = onset of
symptoms, and 126 days of age = end-stage/loss of righting reflex.
Galectin-3 protein expression was also ~12-fold greater
in spinal cords from patients with sporadic ALS, relative
to age-matched controls who died from other causes
(Fig. 2a and b). Galectin-9 protein was approximately
4-fold higher in spinal cords from patients with ALS,
whereas galectin-1 was not significantly altered.
To determine which cells express galectin-3, lumbar
spinal cord sections from patients with ALS or B6SJL
SOD1G93A mice were double stained with antibodies to
galectin-3 and several cell-type specific marker proteins
and visualized with a fluorescent microscope. Galectin-3
was primarily expressed by microglia (Iba1-microglial
marker, thick arrows), was also occasionally observed in
astrocytes (GFAP-astrocyte marker, thin arrows; Fig. 2c
and d), but was not typically expressed in neurons. Galectin-3 was also primarily expressed in microglia in B6 SJL
SOD1G93A mice, at 90 (Fig. 3) and 130 days of age (data
not shown).

Deletion of galectin-3 accelerates disease
progression and weight loss, diminishes
motor function, and reduces life span of
SOD1G93A mice
To avoid confounding effects of background strain,
C57BL6 SOD1G93A mice were used to create the
SOD1G93A galectin-3 knock-outs. SOD1G93A mice on the
C57BL6 background have a longer life span than
SOD1G93A mice on the B6SJL strain, with end-stage disease (50% survival) typically occurring at around 160 versus 130 days of age, respectively (Gurney et al. 1994).
Deletion of galectin-3 in SOD1G93A diseased (C57BL6
SOD1G93A/Gal-3 / ) mice did not alter the date of the
first appearance of a neurobehavioral defect (onset), but
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Figure 1. Galectins are specifically and differentially expressed in the spinal cord of mice with chronic motor neuron disease. (a) Heat map of
galectin mRNA transcripts expressed over time as detected by microarray analyses of spinal cords from B6SJL SOD1G93A versus control B6SJL (WT)
mice (n = 3 per genotype). Each column represents the signal from a specific galectin probeset (1426808_at=galectin-3, 1421217_a_at=galectin-9,
1419573_a_at=galectin-1), and each line of bars represents mouse age (in days). Expression signal intensities are depicted as colors ranging
from high (orange/warm) to low (green/cool), relative to the signal of all controls combined. Asterisks indicate significant differences from
controls of equivalent age (P < 0.05 by Student’s t-test comparison). In this strain, disease onset occurs at ~98 days of age, and end-stage
disease at ~130 days of age. (b) Elevated levels of galectin-3 are restricted to the spinal cord, rather than other CNS regions or muscle.
Galectin-3 protein levels were assessed with Western blots of homogenates prepared from the cortex, cerebellum, gastrocnemius muscle, and
spinal cord of 126-day-old wild-type (WT) and B6SJL SOD1G93A mice (n = 3 per genotype). (c) Expression of galectin-3 is elevated early in the
spinal cord during motor neuron disease progression, followed by increases in galectins-9 and -1. Western blots were prepared from spinal
cord homogenates of 70-, 98-, and 126-day-old B6SJL SOD1G93A mice and age-matched strain controls (n = 3 per genotype). Blots were
quantified, and optical densities of galectins expressed as the galectin:actin ratio as a percent of age-matched strain controls (*P < 0.05;
***P < 0.001 compared with controls by Student’s t-test). Representative blots are shown below (d).

it hastened progression to more severely impaired disease
stages (Fig. 4). In addition, the survival of C57BL6
SOD1G93A/Gal-3 / mice was reduced by 25 days compared with C57BL6 SOD1G93A/Gal-3+/+ controls. C57BL6
SOD1G93A/Gal-3 / mice also scored poorly compared
with C57BL6 SOD1G93A/Gal-3+/+ mice on the standard
functional tests (vertical rise, rotarod, hind limb grip
strength; Fig. 5). Prior to disease onset, C57BL6
SOD1G93A/Gal-3 / mice had increased body weight
compared with C57BL6 SOD1G93A/Gal-3+/+ mice (Fig. 5).
However, starting at week 17, C57BL6 SOD1G93A/Gal-3 /
mice had an acceleration of weight loss relative to
C57BL6 SOD1G93A/Gal-3+/+ cohorts.
Western blots confirmed elevation of galectin-3 in the
C57BL6 SOD1G93A/Gal-3+/+ strain, and that deletion of
galectin-3 abolished galectin-3 expression (Fig. 6). Galec-
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tin-3 was also not elevated in either C57BL6 SODWT/
Gal-3+/+ or C57BL6 SODWT/Gal-3 / mice (Fig. 6), and
C57BL6SODWT/Gal-3 / control mice showed no evidence of functional impairment or decreased life span.

Deletion of galectin-3 increases microglial
activation, TNF-a levels, and oxidative injury
in SOD1G93A mice
Sections were immunostained for the microglial marker
Iba1 and positive cells visualized in mice at 70 days of
age and at end stage of disease (Fig. 7a and b). There
were slightly more Iba1 positive cells in C57BL6
SOD1G93A/Gal-3+/+ controls versus C57BL6 SOD1G93A/
Gal-3 / mice at 70 days of age, but the difference was
not marked. However, Iba1 positive cells were increased
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Figure 2. Expression of galectin-3 and -9, but not galectin-1 is elevated in patients with sporadic amyotrophic lateral sclerosis (ALS), and
galectin-3 is expressed by microglia. Galectin levels in spinal cord homogenates from patients with sporadic ALS (n = 5) were compared with
human controls of approximately equal age who died from other causes (n = 4), via Western blotting methods. (a) Blots were quantified as
optical densities of galectins expressed as the galectin:actin ratio as a percent of optical densities from controls (**P < 0.01 or ***P < 0.001 by
Student’s t-test comparisons). (b) Images of Western blots quantified in (a). (c and d) Galectin-3 is primarily expressed by microglia in spinal cords
from patients with sporadic ALS. Immunocytochemistry of transverse sections of human spinal cords from control subjects (c) and from subjects
with sporadic ALS (d) is shown with double staining for galectin-3 (red) and cellular marker proteins (green). In subjects with ALS, galectin-3
predominantly colocalized with microglia cell marker Iba1 (merged-top row; thick arrows/yellow), rather than with the astrocytic specific marker
GFAP (merged-bottom row, thin arrow/yellow).

at end stage relative to 70 days of age for both genotypes
– and there was a marked increase in Iba1 positive cells
in C57BL6 SOD1G93A/Gal-3 / compared with agematched C57BL6 SOD1G93A/Gal-3+/+ controls at this
time. To determine whether activation of microglia may
correlate with enhanced inflammation, the level of TNF-a
in the spinal cord of diseased mice was measured at end
stage of disease. TNF-a in the lumbar spinal cord of
C57BL6 SOD1G93A/Gal-3 / mice was higher than in
C57BL6 SOD1G93A/Gal-3+/+ controls (Fig. 7c). To evaluate whether the observed exacerbation of neuroinflammation in C57BL6 SOD1G93A/Gal-3 / mice was associated
with oxidative damage, protein carbonyls were quantified.
Protein carbonyls are formed by free radical mediated
amino acid (proline, arginine, lysine, and threonine)
modification. Total protein carbonyl content was nearly
doubled in C57BL6 SOD1G93A/Gal-3 / mice compared
with C57BL6 SOD1G93A/Gal-3+/+ controls (Fig. 7d).
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Discussion
The glial-derived neuroinflammatory microenvironment
can significantly alter the progression of ALS. The present
data show progressive increases in expression of several
galectins in the spinal cord of the SOD1G93A murine
model of ALS. Galectin-3 protein expression was initially
elevated at the presymptomatic stage of disease
(10 weeks), and increased through end stage. It was also
confined to the spinal cord and thus appears to be specifically associated with the ongoing degenerative process
there. The primary source of galectin-3 in the SOD1G93A
mouse and in humans with ALS was activated microglia,
as it was only occasionally observed in astrocytes or neurons. Expression of galectin-9 increased after symptoms
appeared, and galectin-1 increased only at the end stage
of disease; therefore, the expression of these galectins represents a later event in disease progression. Further, only
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Figure 3. Galectin-3 is primarily expressed by microglia and some astrocytes in the B6SJL SOD1G93A spinal cord. Representative images of
transverse sections of the lumbar spinal cord from 90-day-old B6SJL SOD1G93A transgenic mice and aged-matched WT controls were colabeled
with antibodies for galectin-3 (red), and with a marker for microglia (Iba1; green; row 1), with an FITC-Nissl fluorescent stain for neurons, or with
a marker for astrocytes (GFAP; green; row 3). Individual and merged images from the same field are presented.

Figure 4. Progression of motor neuron disease is more rapid and life span is decreased in C57BL6 SOD1G93A/Gal-3 / mice (n = 12) compared
with C57BL6 SOD1G93A/Gal-3+/+ controls (n = 12). A neurological assessment rating scale from score 4 (no visible sign of disease) to 0 was used
to assess disease progression. Each graph represents the % of mice with scores 3 through 0 for each genotype over time, where 3 = altered hind
limb extension/tremors on suspension by the tail (aka failed “splay” test), but otherwise visually normal, 2 = deficits on “splay” test and
additional functional tests (grip, activity, or rotarod), but no visually obvious abnormalities; 1 = deficits on all tests and visually observable uni- or
bilateral paralysis; and 0 = deficits on all tests, visually obvious uni- or bilateral paralysis, and fails righting reflex test. The P-values shown
represent the Kaplan–Meier statistical analysis result for comparisons of the genotypes at each disease stage/score as indicated on the y-axis.
Animals that received a score of 0 were removed from the study and considered expired, and thus, the graph of mice with score = 0 is
equivalent to a Kaplan–Meier survival curve.
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Figure 5. The C57BL6 SOD1G93A/Gal-3 / phenotype (n = 12) displays greater functional impairment and weight loss than the C57BL6
SOD1G93A/Gal-3+/+ cohort (n = 12) during disease progression. Mean ± SEM scores of C57BL6 SOD1G93A/Gal-3 / or C57BL6 SOD1G93A/Gal-3+/+
control mice are graphed over time for individual tests of motor function or body weight. The vertical rise score reflects the number of times
animals reared up onto their hind limbs to explore during 3 min in an open field chamber. Rotarod and grip strength tests are detailed in
Methods. For all, *P < 0.05 by two-way ANOVA followed by individual post hoc t-tests for each time point.

Figure 6. Verification that galectin-3 is increased with SOD1G93A mutation on the C57BL6 background strain and is abolished in the SOD1G93A/
Gal-3 / phenotype. Western blots were prepared from spinal cord homogenates obtained at the end stage of disease (126 days of age) in
SOD1G93A/Gal-3+/+, SOD1G93A/Gal-3 / , SOD1WT/Gal-3+/+, and SOD1wT/Gal-3 / (n = 3 per genotype) animals. A representative blot is shown in
(a), with the mean ± SEM optical density of galectin-3 signal normalized to actin graphed for all blots/groups shown in (b) *P < 0.005 versus
SOD1G93A/Gal-3 / by Student’s t-test comparison.
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Figure 7. IBA1 positive cells (microglia), TNF-a, and oxidative injury are increased in C57BL6 SOD1G93A/Gal-3 / mice compared with C57BL6
SOD1G93A/Gal-3+/+ controls at the end stage of motor neuron disease. Sections from either (a) 70-day-old or (b) end-stage (loss of righting reflex)
lumbar spinal cords (n = 6 for each genotype, at each time point) were stained with anti-IBA1. Representative images are shown. (c) TNF-a and
oxidative injury (d) are increased in C57BL6 SOD1G93A/Gal-3 / mice compared with C57BL6 SOD1G93A/Gal-3+/+ controls (n = 4 for each
genotype) at the end stage of motor neuron disease. TNF-a and protein carbonyls (as markers of oxidative protein modification) were assessed in
homogenates from lumbar spinal cords using ELISA assays (*P < 0.05 by Student’s t-test). TNF-a levels are expressed as mean ± SEM absolute
absorbance values. Carbonyls were derived from a standard curve prepared from reduced oxidized BSA standards and expressed as mean ± SEM
nmol/pg protein.

galectin(s)-3 and galectin-9 were increased in human
postmortem spinal cords of patients with sporadic ALS.
Our study using Western blots did not detect galectin1 in patients with ALS, but others have localized it to
neurofilamentous lesions associated with the disease (Kato
et al. 2001). The discrepancy may reflect methodological
differences, as the Western blots used here may not detect
subtle, localized changes that are visualized with histology.
Notably, intramuscular administration of oxidized galectin-1 improved neurological function and extended survival in a mutant SOD1 mouse model of ALS (ChangHong et al. 2005).
To our knowledge, the present data are the first to
identify elevated galectin-9 associated with motor neuron
disease and ALS. In vitro, galectin-9 is expressed by astrocytes stimulated with IL-1b (Yoshida et al. 2001), and this
effect is abolished by dexamethasone, suggesting that
galectin-9 is produced as part of neuroinflammation
induced by pro-inflammatory cytokines. However, we
speculate that it may potentially reduce inflammation, as
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galectin-9 is a ligand for T-cell immunoglobulin mucin(TIM)-3, and activation of the galectin-9-TIM-3 pathway
suppresses Th1 immune responses (Zhu et al. 2005).
Galectin-9 also reduces secretion of TNF-a and IL-1b and
increases IL-10 production in stimulated peritoneal macrophages (Arikawa et al. 2009). Additional studies are
needed to determine the functional role of galectin-9 in
ALS.
In agreement with previous reports (Yamanaka et al.
2008; Saxena et al. 2009; Hossiani et al. 2011), our data
implicate microglia as the major source of galectin-3 associated with chronic motor neurodegeneration. However,
others noted galectin-3 (but not galectin-1 or -9) mRNA
increased in motor neurons from late-stage disease
(~17 weeks) SOD1G93A mice (Ferraiuolo et al. 2007).
Expression profiling methods also detected galectin-1 and
-3 mRNA in spinal cord and skeletal muscle of paralyzed
SOD1G86R mice at 15 weeks of age (Gonzalez de Aguilar
et al. 2008). Increased galectin-3 protein was recently
observed in spinal cords from SOD1G93A mice and
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patients with ALS (Zhou et al. 2010), where it was also
observed in CSF, and suggested that it may be a potential
clinical biomarker of motor neuron disease. The present
data extend such observations by showing that the initial
elevation of galectin-3 occurs even in the presymptomatic
stage of disease, and that it increases further from that
point.
We generated C57BL6 SOD1G93A/Gal-3 / knock-out
transgenic mice, to evaluate the effect of galectin-3 deletion on the diseased phenotype. Mice with the galectin-3
deletion on the pure (undiseased) C57BL6 background
have been characterized as viable and fertile, with the
same body and organ weights as galectin-3+/+ cohorts
(Hsu et al. 2000). In initial observations, they displayed
no overt behavioral defects, no abnormalities in blood
chemistry or cell counts, and histological evaluation
revealed no gross abnormalities of major organs, including brain. Indeed, C57BL6 SODWT/Gal-3 / mice did not
perform significantly different from C57BL6 SODWT/Gal3+/+ animals at any point in the present study. C57BL6
galectin-3 / mice <90 days of age also performed identically to controls on locomotor, hole-board, or inverted
screen tests in another recent study; however, they displayed an increased percentage of open arm entries in a
plus-maze test, suggesting reduced anxiety (Pasquini et al.
2011). Moreover, histological analysis revealed defects in
myelin structure and oligodendrocyte differentiation.
Thus, these features of the C57BL6 galectin-3 / phenotype may be present in SOD1G93A/Gal-3 / transgenics,
although we did not perform histology to verify that, so
this issue remains unresolved.
Galectin-3 deletion did not alter disease onset, though
SOD1G93A/Gal-3 / mice progressed faster through all
stages of disease and expired, on average, 25 days earlier
than their SOD1G93A/Gal-3+/+ cohorts. SOD1G93A/Gal-3 /
mice also scored significantly worse on all functional
tests relative to SOD1G93A/Gal-3+/+ mice, indicating that
the SOD1G93A/Gal-3 / phenotype was severely impaired,
and suggesting that galectin-3 deletion may have
increased neurodegeneration. Deletion of galectin-3 was
also associated with an increase in microglia, and elevated
levels of TNF-a and protein carbonyls, a marker of oxidative injury.
Microglial number and phenotype significantly influence the progression of motor neuron disease. Increases
in wild-type (non-SOD1G93A) microglia reduced neurodegeneration slowed disease progression and increased survival of SOD1G93A mice, supporting a generally protective
role for healthy microglia against the disease process
(Beers et al. 2006). Alternatively, selective reduction of
SOD1 overexpression within diseased microglia increased
survival time, particularly at the end stage of disease
(Boillee et al. 2006; Wang et al. 2010), suggesting that
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mSOD1 imparts neurotoxic properties to microglia that
contribute to neurodegeneration. Indeed, SOD1G03A
microglia display an inflammatory phenotype characterized by elevations in TNF and other inflammatory
molecules (Sargsyan et al. 2009). Thus, the presence of
more SOD1G93A microglial cells in the SOD1G93A/Gal-3 /
cohort may have increased the neurotoxic/pro-inflammatory load on neurons, and accelerated disease progression. Also possible, is that deletion of galectin-3 further
enhanced the already neurotoxic properties of the
mSOD1G93A microglia. This is indirectly supported by
data showing that a 50% reduction in the number of proliferating galectin-3/Mac-2+ mutant (mSOD1) microglia
in CD11b-TKmut 30, SOD1G93A doubly transgenic mice
had no effect on neurodegeneration (Gowing et al. 2008).
Increased protein carbonyls correlate with an upregulation of TNF-a transcripts at an early stage of disease in
SOD1G93A mice (Hensley et al. 2006). TNF-a elevation
also correlates with disease progression in the mouse, and
TNF-a is increased in serum from ALS patients (Poloni
et al. 2000; Hensley et al. 2003). Although the precise role
of TNF in disease progression is unclear (Gowing et al.
2006), it has many pro-inflammatory effects, including
activation and stimulation of free radical release from
microglia, as well as potential synergisms with other
pathogenic factors involved in the disease (McGeer and
McGeer 2002; Mir et al. 2009). While the present studies
do not address any direct relationship between TNF-a
and oxidative injury, the observation that both were
increased in SOD1G93A/Gal-3 / mice supports that
neuroinflammation was exacerbated in the absence of
galectin-3.
Though not always consistent (Doverhag et al. 2010),
some evidence suggests a protective role for galectin-3+/
Mac-2 expressing microglia, at least in models of acute
neurodegeneration (Lalancette-Hebert et al. 2007). Such
protection is associated with transition of microglia to a
galectin-3 positive alternative activation phenotype (M2)
that expresses increased levels of IGF-1 and a type Th2
immune bias (Ohtaki et al. 2008). Importantly, deletion
of galectin-3 from macrophages renders them unable to
assume the M2 phenotype (MacKinnon et al. 2008). In
addition, galectin-3 is known to be involved in a variety
of physiological phenomena associated with alternative
activation, as it promotes wound healing, angiogenesis,
and growth and proliferation of neural progenitors
(Pesheva et al. 1998; Cao et al. 2002; Yan et al. 2009).
Considered together with our data, these observations
support the speculation that deletion of galectin-3 may
have eliminated the trophic and reparative effects of an
alternatively activated microglial phenotype in the
SOD1G93A/Gal-3 / cohort and that an activated proinflammatory (M1) microglial phenotype may have pre-
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dominated in the SOD1G93A/Gal-3 / microenvironment.
Nevertheless, any such effect on neuroinflammation may
be conditionally dependent, as galectin-3 depletion
reduced inflammation and the severity of experimental
autoimmune encephalitis (Jiang et al. 2009), and reduced
pain due to macrophage invasion in herpes zoster
induced allodynia (Takasaki et al. 2012).
Although this study focuses on neuroinflammation,
galectin-3 is pleiotropic and may modulate other factors
involved in motor neuron disease. For example, intracellular galectin-3 directly influences necrotic and apoptotic
cell death pathways, as well as autophagy (Yu et al. 2002;
Mok et al. 2007). Galectin-3 is also an advanced glycation
end-product (AGE) receptor (RAGE) that targets AGE for
lysosomal degradation and removal (Pricci et al. 2000).
As AGE are a source of inflammation and oxidative
injury both in ALS and mouse models of ALS (Kato et al.
2000), deletion of galectin-3 may enhance neurodegeneration due to AGE accumulation. Glycoprotein receptors
for T cells, trophic factors (EGF, IGF), and cytokines with
the consensus sequence (N-X-S/T) also contain N-acetyllactosamines, which are preferred binding substrates for
extracellular galectin-3 (Rabinovich et al. 2007). Galectin3 forms cross-linked lattices with these residues that alter
downstream cell signaling and inflammatory pathways
(reviewed in Boscher et al. 2011), and such interactions
would likely be reduced by galectin-3 deletion. In addition, as noted previously, galectin-3 deficient mice have
defects in myelin integrity and reduced oligodendrocyte
differentiation, and these may have influenced functional
outcome both in controls and in the SOD1G93A transgenics (Pasquini et al. 2011). Galectin-3 may also influence
neuroblast migration in the developing brain (Comte
et al. 2011). Although we have not addressed any of these
mechanisms in the present report, they may have contributed to our observations.
Finally, although it is interesting to speculate that there
may be differences in galectin-3 expression and related
inflammatory changes between C57/B6 G93A SOD1 and
SJL SOD1G93A mice that contribute to the overall
significantly faster disease progression in the SJL
SOD1G93A strain, it is worth noting that the pure SJL/J
strain has reduced levels of dysferlin, altered macrophage
activity, early functional impairment, and indeed is used
as a model of limb girdle muscular dystrophy type 2B
(Rayavarapu et al. 2010). If and how these traits may
potentially contribute to SJL 9 C57/B6 strain-specific
onset/progression and drug response characteristics in
hSOD1 transgenics is unclear.
In conclusion, the present data indicate that galectin
(s)-3 and -9 are increased in ALS and an SOD1G93A
mouse model of ALS. Galectin-3 is primarily expressed by
microglia in the SOD1G93A mouse model of ALS, and in
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humans with ALS. Deletion of galectin-3 in the SOD1G93A
mouse resulted in rapid disease progression, and increases
in microglia, TNF-a, and oxidative injury, compared with
galectin-3 expressing SOD1G93A diseased controls. Thus,
endogenous production of galectin-3 by microglia may, at
least in part, serve to limit neuroinflammation and disease progression during chronic motor neurodegenerative
disease.
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